Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • Neurodegeneration
  • 6

Filter Results (173)

  • Research Grant, 2015
    Phase IB Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A in Those Who Participated in the AFF008 Program

    Promising Outcomes of Original Grant:
    Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease (PD), and its reduction is expected to positively modify...

  • Target Validation, 2015
    Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression

    Study Rationale:                             
    A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s...

  • Target Validation, 2015
    Synapsin III: A Novel Therapeutic Target for Parkinson’s Disease

    Objective/Rationale: 
    In Parkinson’s disease (PD) accumulation of alpha-synuclein at striatal synapses, the neuronal sites of dopamine release, is believed to trigger cell degeneration. We have found...

  • Research Grant Supplement, 2015
    The Influence of Bacterial Amyloid on Alpha-synuclein Misfolding in a Pre-clinical Model Supplement

    Promising Outcomes of Original Grant:
    We hypothesized that that deposits of the Parkinson’s disease-associated protein alpha-synuclein in gut and brain neurons are caused by exposure to proteins of...

  • Research Grant, 2014
    PARK14-dependent SOCE and Sporadic Parkinson’s Disease

    Objective/Rationale:             
    Mutations in the PARK14 gene are associated with Parkinson’s disease (PD), but its role in idiopathic PD is presently unknown. Recently we identified a role of PARK14...

  • Rapid Response Innovation Awards, 2014
    GSNOR Inhibition for Treatment of Parkinson’s Disease

    Study Rationale:                    
    Parkinson’s disease may be driven by inflammation and toxic, reactive products from oxygen metabolism. SAJE Pharma’s drugs target an enzyme called s...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.